Bristol Myers’ Zenbexus approval was framed by investors and analysts as a “milestone” outcome for CELMoDs, the company’s new myeloma drug class acquired from Celgene. The FDA’s accelerated decision brings the iberdomide-containing regimen into a competitive second-line landscape already dominated by daratumumab-based standards. The approval is based on Phase 3 data showing superiority in achieving MRD-negative status relative to a Velcade-based regimen. Reported MRD-negative rates were 41% for Zenbexus versus 21% for Velcade, with additional endpoints such as delay of disease progression still under evaluation. Analysts highlighted commercialization implications, including the potential for iberdomide to shift prescribing dynamics among second-line options and a path toward further studies such as a maintenance trial after transplant.